ATMA Journey Centers

ATMA Journey Centers is pioneering a healthcare practitioner-centric business model for the psychedelics industry. By providing education, training, clinical trials leading to IP protocols, support services, and developing a network of clinics, it is building and supporting a large community of psychedelic practitioners adopting psychedelic-assisted therapies, thereby improving accessibility for many. Focused primarily on advancing innovative psychedelic-assisted treatment solutions, it has received approval for a Phase II psilocybin-assisted therapy clinical trial from the Health Research Ethics Board of Alberta (HREBA) and Health Canada (No Objection Letter). The primary objective of the trial is to evaluate the potential of psilocybin-assisted therapy in treating frontline mental health care professionals diagnosed with Major Depressive Disorder (MDD), both in group and individual settings.